Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PDE8B | O95263 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30165850 | 0.78 | HSD17B10 (0.39) | ALDH1A1HSD17B10MEN1KMT2AL3MBTL1 | |
| SCHEMBL30165822 | 0.78 | HSD17B10 (0.39) | ALDH1A1HSD17B10MEN1KMT2AL3MBTL1 | |
| SCHEMBL27918465 | 0.77 | ROCK2 (0.40) | ALDH1A1HSD17B10MEN1KMT2AL3MBTL1 | |
| SCHEMBL31411007 | 0.76 | USP2 (0.50) | ATMALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL3061518 | 0.75 | GPR119 (0.39) | ATMUSP2SMN1; SMN2 | |
| SCHEMBL2397802 | 0.75 | RECQL (0.50) | HPGDUSP2SMN1; SMN2 | |
| SCHEMBL9047694 | 0.74 | PREP (0.50) | ALDH1A1MEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL21783062 | 0.73 | USP30 (0.52) | HPGDUSP2SMN1; SMN2 | |
| SCHEMBL1202111 | 0.73 | HPGD (0.49) | ALDH1A1HSD17B10HPGDNPC1SMN1; SMN2 | |
| SCHEMBL7002987 | 0.73 | HPGD (0.49) | ALDH1A1HSD17B10HPGDNPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| WO-2003037271-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS,INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | ATM 4854/4885ALDH1A1 1071/4885HSD17B10 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.